Evidence map›Paper›PMID 37421263›Full record

ArticleJournal of the American Heart Association2023

Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population-Based Investigation.

Osung Kwon, Jun-Pyo Myong, Yunhee Lee, Yeon-Jik Choi, Jeong Eun Yi, Suk Min Seo, Sung-Won Jang, Pum Joon Kim, Jung-Min Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 9 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 9 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Osung KwonDivision of Cardiology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital College of Medicine, The Catholic University of Korea Seoul Republic of Korea.ORCID 0000-0001-6857-8632
Jun-Pyo MyongDepartment of Occupational & Environmental Medicine, Seoul St. Mary's Hospital College of Medicine, The Catholic University of Korea Seoul Republic of Korea.ORCID 0000-0001-8674-1034
Yunhee LeeDepartment of Urology, Seoul St. Mary's Hospital College of Medicine, The Catholic University of Korea Seoul Republic of Korea.ORCID 0000-0002-9177-2553
Yeon-Jik ChoiDivision of Cardiology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital College of Medicine, The Catholic University of Korea Seoul Republic of Korea.
Jeong Eun YiDivision of Cardiology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital College of Medicine, The Catholic University of Korea Seoul Republic of Korea.
Suk Min SeoDivision of Cardiology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital College of Medicine, The Catholic University of Korea Seoul Republic of Korea.ORCID 0000-0003-2424-5275
Sung-Won JangDivision of Cardiology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital College of Medicine, The Catholic University of Korea Seoul Republic of Korea.ORCID 0000-0001-5272-0665
Pum Joon KimDivision of Cardiology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital College of Medicine, The Catholic University of Korea Seoul Republic of Korea.
Jung-Min LeeDivision of Endocrinology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital College of Medicine, The Catholic University of Korea Seoul Republic of Korea.ORCID 0000-0003-4153-3834
Catholic University of Korea · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Whether the early use of sodium-glucose cotransporter-2 (SGLT2) inhibitors have cardioprotective effects following acute myocardial infarction is unknown. Thus, we aimed to evaluate the association between the early initiation of SGLT2 inhibitors and cardiac event rates in patients with diabetes with acute myocardial infarction undergoing percutaneous coronary intervention. Methods and Results Based on the National Health Insurance claims data in South Korea, patients who received percutaneous coronary intervention for acute myocardial infarction between 2014 and 2018 were analyzed. Patients given SGLT2 inhibitors or other glucose-lowering drugs were matched based on a propensity score. The primary end point was a composite of all-cause mortality and hospitalizations for heart failure. Major adverse cardiac events (a composite of all-cause death, nonfatal myocardial infarction, and ischemic stroke) were compared as the secondary end point. After 1:2 propensity score matching, the SGLT2 inhibitors group (938 patients) and the no use of SGLT2 inhibitors group (1876 patients) were compared. During a median follow-up of 2.1 years, the early use of SGLT2 inhibitors was associated with lower risks of both the primary end point (9.8% versus 13.9%; adjusted hazard ratio [HR], 0.68 [95% CI, 0.54-0.87];

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Heart FailureMyocardial InfarctionSodium-Glucose Transporter 2 InhibitorsGlucoseHumansSodiumGlucoseSodiumSodium-Glucose Transporter 2 Inhibitorsacute myocardial infarctiondiabetesheart failuremortalitysodium‐glucose cotransporter 2 inhibitors

Identifiers

PMID37421263
PMCPMC10382092
OpenAlexW4383620886

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.